moderna

Moderna stock soared on positive Phase 3 results for its personalized melanoma vaccine with Merck, prompting Morgan Stanley to raise its price target to $89 from $39.

Investors sold despite positive melanoma vaccine trial results, pointing to lingering doubts about Moderna's ability to execute beyond COVID and generate sustainable returns.

Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.